I recently picked up an Ivermectin prescription from a local compounding pharmacy after my doctor described it for my use in case I come down with COVID-19. To increase my resistance against the virus, I also follow the daily regimen below.
It is not hard to see that Big Pharma along with the NIH, CDC, medical associations, and the mainstream media have put forth an all-out effort to suppress the truth about the effectiveness of Ivermectin.
The American Journal of Therapeutics document titled, “Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines” concludes as follows:
Given the evidence of efficacy, safety, low cost, and current death rates, Ivermectin is likely to have an impact on the health and economic outcomes of the pandemic across many countries.
Ivermectin is not a new and experimental drug with an unknown safety profile. It is a WHO “Essential Medicine” already used in several different indications, in colossal cumulative volumes.
Corticosteroids have become an accepted standard of care in COVID-19, based on a single RCT of dexamethasone. If a single RCT is sufficient for the adoption of dexamethasone, then a fortiori the evidence of 2 dozen RCTs supports the adoption of Ivermectin.
Ivermectin is likely to be an equitable, acceptable, and feasible global intervention against COVID-19.
Health professionals should strongly consider its use, in both treatment and prophylaxis.
Dr. John Campbell compares Pfizer’s Paxlovid™ and Ivermectin.
Additional Reference Materials Provided By Dr. Campbell:
New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄ PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-rel…
So, what is a protease?
So what is a protease inhibitor?
And, what is 3CL?
Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)
Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020) https://pubs.acs.org/doi/abs/10.1021/…
The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds
Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection https://pubs.rsc.org/en/content/artic…
The strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have a place as the drug interacts with the main subdomains that define the enzyme binding pocket:
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
As shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration.
Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly.
Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study https://pubs.rsc.org/en/content/artic…
From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1 https://bnf.nice.org.uk/medicinal-for…
Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach https://www.ncbi.nlm.nih.gov/pmc/arti…
We have documented an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6. PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-rel…
Risk of the virus developing resistance to PF-07321332
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 https://www.frontiersin.org/articles/… With SARS-CoV-2 S Spike protein
Ivermectin showed a high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2.
In agreement with our findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor
Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein)
The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein-ligand interactions
Binding Interactions of Selected Drugs With Human ACE-2 Protein that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein-ligand interactions With SARS-CoV-2 S Glycoprotein
Ivermectin showed the highest binding affinity to the predicted active site of the protein With SARS-CoV-2 Nsp14 Protein
Ivermectin showed the highest binding affinity (MolDock score −212.265) and protein-ligand interactions Binding
Interactions of Selected Drugs With SARS-CoV-2 PLpro Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein-ligand interactions